GlassScriptPhysician profile
Marina Messinger
NPI 1902192677
$7,048.90
in general payments reported to CMS, 2019-2025
58 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $219 · 2021: $900 · 2022: $1,154 · 2023: $1,291 · 2024: $1,274 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.14 |
| Education | $114.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $932.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $585.19 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Genentech USA, INC. | $516.31 | 2019-2025 | Tecentriq, Lunsumio, Columvi |
| Pfizer INC. | $372.20 | 2019-2025 | |
| Janssen Biotech, INC. | $361.00 | 2019-2025 | Rybrevant, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $359.74 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Abbvie INC. | $275.74 | 2022-2025 | |
| Seagen INC. | $253.18 | 2019-2023 | Padcev, Adcetris |
| Gilead Sciences, INC. | $248.33 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $239.73 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $226.24 | 2023-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $188.37 | 2019-2023 | |
| Amgen INC. | $176.04 | 2019-2023 | Lumakras, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $152.09 | 2019-2024 | Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $149.68 | 2019-2025 | Padcev, Vyloy |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Messinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.